Octapharma’s balanced portfolio built on a very special juice
| 21. Apr. 2018
Über diesen Artikel
Article Category: In My View
Online veröffentlicht: 21. Apr. 2018
Seitenbereich: 35 - 37
DOI: https://doi.org/10.17225/jhp.00023
© 2018
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair